Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
Meet the Team
Scrip Awards
Scrip 100
Scrip Asia 100
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Free Trial Request
Subscribe
Advertise
UsernamePublicRestriction

Ian Haydock

Tokyo, Japan
Ian is head of pharma news content for the Asia-Pacific area and has been covering the region for more than 20 years as an editor for Scrip and more recently as managing editor of PharmAsia News. He has a long background in Asia, having grown up in Hong Kong, and a particular interest in regional regulatory harmonization and trade initiatives and the development of the Japanese pharma sector. Ian lives in Tokyo with his wife and two sons.
Advertisement
Set Alert for Articles By Ian Haydock
Cancel
Remove Alert

Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Latest From Ian Haydock

Bookmark
  • Analysis

Mylan Looks To Expedite Biosimilar Humira in EU Through Kyowa Deal

By Anju Ghangurde and Ian Haydock
Mylan has acquired commercial rights in Europe to Kyowa Hakko Kirin's biosimilar adalimumab, paving the way to an early market entry through the product, which could be approved in the second half of this year. But might there be a shift in the commercialization outlook for its partnered adalimumab with Biocon?
India Europe
Bookmark
  • Analysis

Can Pharmas Come Out Unscathed As China-US Trade War Escalates?

By Brian Yang, Anju Ghangurde and Ian Haydock

As a simmering trade dispute between the US and China looks set to continue worsening, many companies in the pharma sector are closely watching what's coming and getting ready for any disruption. But what is the actual and predicted impact on exporters and producers in China, India and the US?

Trade China
Bookmark
  • Analysis

Japan Price Reforms - Major Takeaways

By Ian Haydock
Japan's complex reimbursement pricing system was further tweaked in April in a bid to raise the bar for innovation while controlling costs. What are the main changes and is industry happy?
Japan Regulation
Bookmark
  • Analysis

Can Pharmas Come Out Unscathed As China-US Trade War Escalates?

By Brian Yang, Anju Ghangurde and Ian Haydock

As a simmering trade dispute between the US and China looks set to continue worsening, many companies in the pharma sector are closely watching what's coming and getting ready for any disruption. But what is the actual and predicted impact on exporters and producers in China, India and the US?

Trade China
Bookmark
  • Analysis

Takeda Sheds Multilab In Brazil As Strategic Priorities Shift

By Ian Haydock

Takeda is selling its Multilab operation in Brazil, in a reversal of a deal to buy the mid-sized company around six years ago to bolster its position and generic/OTC portfolios in the country.

Brazil Commercial
Bookmark
  • Analysis

Deal Watch: Allogene Gets Pfizer's Off-The-Shelf CAR-T Program, $300m Series A Backing

By Joseph Haas, Ian Haydock and Jung Won Shin
Celgene reworks its collaboration with Abide, dropping its buyout option. Roivant gains Chinese rights to anti-infective lemafulin and adds a fifth candidate to Dermavant's pipeline, while pSivida acquires Icon and FDA-approved Dexycu for cataract surgery inflammation.
Deals Business Strategies
See All
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By